Adult Sickle Cell Clinical Trials

Current Adult Sickle Cell Clinical Trials

Study: HIBISCUS-2

Study title: A Global Phase 3, Randomised, Double-blind and Placebo-controlled Study Evaluating the Efficacy and Safety of Etavopivat in Adolescents and Adults With Sickle Cell Disease (HIBISCUS 2)

This study is conducted to confirm whether Etavopivat works well at reducing the number of Vaso-occlusive crisis VOCs (sickle cell pain crises) caused by obstructions in blood vessels in adults and adolescents living with sickle cell disease. The study will also evaluate how well etavopivat can reduce the damage to different organs, improve your exercise tolerance and reduce fatigue in people with sickle cell disease. The participants will either get Etavopivat or placebo. Which treatment the participants will get is decided by chance. Etavopivat is a new medicine and is currently being tested in other studies in addition to this one. The study will last for about 2 years.

NCT Number: NCT06612268

Study: The GRNDaD Registry

Study title: The Globin Research Network for Data and Discovery (GRNDaD) Protocol

The primary objective of this research is to create a multi-site registry to collect longitudinal data on a well-documented phenotypic cohort of people with sickle cell disease (SCD) in order to examine risk factors for end organ disease and better understand how clinical characteristics predict outcomes.